Mediators of Inflammation / 2014 / Article / Tab 1 / Research Article
Can the TLR-4-Mediated Signaling Pathway Be “A Key Inflammatory Promoter for Sporadic TAA”? Table 1 Demographic and clinical characteristics, comorbidity conditions, and pharmacological treatment of 161 patients affected by sporadic TAA, 128 control subjects, and 30 aorta controls.
Variables Patients
) Male
) Female
) Controls
)
Aorta Controls
) Demographic characteristics Age, mean (SD) 63 (10.7) 63 (11) 64 (9)
61.1 (5.8) 0.834 0.594 63.9 (10.3) Male sex, number (%) 127 (78) 61 (47) Female sex, number (%) 34 (22) 67 (53) Body mass index, mean (SD) 27 (4.3) 26.9 (3.8) 27.5 (5.6) 26.9 (2.9) 0.898 0.963 25.6 (2.9) Size and location Size (mm), mean (SD) 53.3 (8) 52.9 (7.5) 55 (9.8) 0 (0) 0.191 0 (0) Location, number (%): 0 (0) 0.198 Ascending aorta 81 (50) 20 (59) 61 (48) Aortic Bulb 18 (11) 1 (3) 17 (13.4) Ascending aorta and Aortic bulb 62 (39) 13 (38) 49 (38.6) Comorbidity conditions, number (%) Cardiovascular Ischemic Familiarity 59 (36.6) 48 (38) 11 (32) 34 (27) 0.089 0.7 1 (3.3) Smoking 73 (45) 67 (53) 6 (18) 66 (51) 0.351 <0.001 3 (10) Hypertension 127 (78.9) 101 (80) 26 (76) 40 (31) <0.001 0.879 2 (6.6) Dislipidemy 37 (23) 30 (24) 7 (21) 20 (16) 0.158 0.886 0 (0) Diabetes mellitus 24 (15) 16 (13) 8 (24) 16 (13) 0.677 0.187 0 (0) Renal failure 5 (3.1) 4 (3.1) 1 (2.9) 0 (0) 0.168 0.621 0 (0) Dissection 18 (11) 5 (15) 13 (10) 0 (0) 0.669 0 (0) Aortic valve pathology, number (%): 0 (0) Normal 90 (56) 71 (56) 20 (59) 0 (0) 0.766 0 (0) Prolapse 21 (13) 17 (13) 3 (9) 0 (0) 0 (0) Vascular calcium fibrosis 50 (31) 39 (31) 11 (32) 0 (0) 0 (0) Aortic valve dysfunction, number (%): Normal 32 (20) 26 (20.4) 6 (17.6) 0 (0) 0.91 0 (0) Faint incontinence 29 (18) 22 (17) 7 (20.4) 0 (0) 0 (0) Moderate incontinence 34 (21) 28 (22) 6 (17.6) 0 (0) 0 (0) Severe incontinence
44 (28) 35 (28) 9 (26.4) 0 (0) 0 (0) Faint stenosis 1 (0.6) 1 (0.8) 0 (0) 0 (0) 0 (0) Moderate stenosis 2 (1.2) 1 (0.8) 1 (3) 0 (0) 0 (0) Severe stenosis 19 (11.2) 14 (11) 5 (15) 0 (0) 0 (0) Atherosclerosis coronary syndrome No (%) 54 (33.8) 45 (36) 9 (26.5) 0 (0) 0.42 0 (0) Drugs, number (%) Beta blockers 62 (39) 47 (37) 15 (44) 0 (0) 0 (0) Central alpha-adrenergic agonists 26 (16) 21 (17) 5 (15) 0 (0) 0 (0) Sartans 32 (20) 27 (21) 5 (15) 0 (0) 0 (0) Calcium-channel blockers 47 (29) 38 (30) 9 (26) 0 (0) 0 (0) ACE inhibitors 66 (41) 55 (43) 11 (32) 21 (16) 0 (0) Antidiabetic drugs 19 (12) 13 (10) 6 (18) 16 (13) 0 (0) Antiaggregant drugs 51 (32) 44 (34) 7 (21) 40 (31) 0 (0) Antidislipidemic drugs 36 (22) 30 (24) 6 (18) 0 (0) 0 (0) Diuretics 36 (22) 24 (19) 12 (36) 40 (31) 0 (0)
